Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.

Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, Torres JL, Kalyuzhniy O, Melzi E, Kulp DW, Raemisch S, Hu X, Bernard SM, Georgeson E, Phelps N, Adachi Y, Kubitz M, Landais E, Umotoy J, Robinson A, Briney B, Wilson IA, Burton DR, Ward AB, Crotty S, Batista FD, Schief WR.

Science. 2019 Dec 6;366(6470). pii: eaax4380. doi: 10.1126/science.aax4380. Epub 2019 Oct 31.

PMID:
31672916
2.

Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan.

Umotoy J, Bagaya BS, Joyce C, Schiffner T, Menis S, Saye-Francisco KL, Biddle T, Mohan S, Vollbrecht T, Kalyuzhniy O, Madzorera S, Kitchin D, Lambson B, Nonyane M, Kilembe W; IAVI Protocol C Investigators; IAVI African HIV Research Network, Poignard P, Schief WR, Burton DR, Murrell B, Moore PL, Briney B, Sok D, Landais E.

Immunity. 2019 Jul 16;51(1):141-154.e6. doi: 10.1016/j.immuni.2019.06.004.

3.

Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design.

Rantalainen K, Berndsen ZT, Murrell S, Cao L, Omorodion O, Torres JL, Wu M, Umotoy J, Copps J, Poignard P, Landais E, Paulson JC, Wilson IA, Ward AB.

Cell Rep. 2018 Jun 12;23(11):3249-3261. doi: 10.1016/j.celrep.2018.05.046.

4.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

5.

Synthesis and Sulfur Electrophilicity of the Nuphar Thiaspirane Pharmacophore.

Tada N, Jansen DJ, Mower MP, Blewett MM, Umotoy JC, Cravatt BF, Wolan DW, Shenvi RA.

ACS Cent Sci. 2016 Jun 22;2(6):401-8. doi: 10.1021/acscentsci.6b00113. Epub 2016 Jun 13.

6.

Nitrosopurines en route to potently cytotoxic asmarines.

Wan KK, Iwasaki K, Umotoy JC, Wolan DW, Shenvi RA.

Angew Chem Int Ed Engl. 2015 Feb 16;54(8):2410-5. doi: 10.1002/anie.201411493. Epub 2015 Jan 7.

7.

Selective inhibition of initiator versus executioner caspases using small peptides containing unnatural amino acids.

Vickers CJ, González-Páez GE, Litwin KM, Umotoy JC, Coutsias EA, Wolan DW.

ACS Chem Biol. 2014 Oct 17;9(10):2194-8. doi: 10.1021/cb5004256. Epub 2014 Aug 5.

PMID:
25079698
8.

Small-molecule procaspase activators identified using fluorescence polarization.

Vickers CJ, González-Páez GE, Umotoy JC, Cayanan-Garrett C, Brown SJ, Wolan DW.

Chembiochem. 2013 Aug 19;14(12):1419-22. doi: 10.1002/cbic.201300315. Epub 2013 Jul 8.

PMID:
23836614

Supplemental Content

Loading ...
Support Center